Skip to main content

Anti-β2-Glycoprotein I Antibodies in Lyme Borreliosis: Differences in Disease Stage and Immunoglobulin Class Distribution

Buy Article:

$68.00 + tax (Refund Policy)

Spirochetes are gram-negative bacteria, which include the Treponema, Borrelia and Leptospira and cause different diseases such as syphilis, Lyme borreliosis and leptospirosis, respectively. Antiphospholipid antibodies as a consequence of the infection with Treponema pallidum subsp. pallidum have been extensively studied. There have also been a few reports of antiphospholipid antibodies in leptospirosis. On the other hand, there are very few data on the presence of antiphospholipid antibodies in Lyme borreliosis and to our knowledge, there is no information about antibodies against β2-glycoprotein I. In this study, we report the frequency of anticardiolipin antibodies and for the first time, the frequency of antibodies against β2-glycoprotein I in patients with acute and chronic Lyme borreliosis. The frequency of anticardiolipin antibodies and IgG antibodies against β2-glycoprotein I was similar in both groups, but antibodies against β2- glycoprotein I of the IgM isotype were surprisingly higher in the late stage of the disease. The frequency of IgM class antibodies against β2-glycoprotein I was 10% in chronic Lyme borreliosis versus none in acute Lyme borreliosis.





Keywords: Lyme borreliosis; acrodermatitis atrophicans; anti-β2-glycoprotein I antibodies; anticardiolipin antibodies; erythema migrans

Document Type: Research Article

Affiliations: Department of Rheumatology, Vodnikova 62, 1000 Ljubljana, Slovenia.

Publication date: 01 November 2006

More about this publication?
  • Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field.

    The journal is essential reading for all researchers and clinicians in rheumatology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content